Last $3.70 USD
Change Today -0.04 / -1.07%
Volume 13.4K
VGEN On Other Exchanges
Symbol
Exchange
OTC US
As of 5:20 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

vaccinogen inc (VGEN) Snapshot

Open
$3.70
Previous Close
$3.74
Day High
$3.70
Day Low
$3.50
52 Week High
03/5/14 - $8.50
52 Week Low
12/31/14 - $1.99
Market Cap
125.9M
Average Volume 10 Days
7.4K
EPS TTM
--
Shares Outstanding
34.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VACCINOGEN INC (VGEN)

Related News

No related news articles were found.

vaccinogen inc (VGEN) Related Businessweek News

No Related Businessweek News Found

vaccinogen inc (VGEN) Details

Vaccinogen Inc., a biotechnology company, focuses on the development and commercialization of cancer vaccines and immunotherapeutic products for cancers and infectious diseases. It primarily offers OncoVAX, a cancer vaccine for the post-surgical treatment of Stage II colon cancer. The company was founded in 2007 and is headquartered in Baltimore, Maryland.

9 Employees
Last Reported Date: 03/28/14
Founded in 2007

vaccinogen inc (VGEN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $250.0K
Founder, Chairman Emeritus, Special Advisor, ...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

vaccinogen inc (VGEN) Key Developments

Vaccinogen, Inc. Relocates Corporate Headquarters to Baltimore

Vaccinogen, Inc. announced that it has relocated its corporate headquarters from Frederick, MD to a 10,000 square-foot facility at 949 Fell Street in Baltimore, MD. The relocation was completed on February 22.

Vaccinogen, Inc. Announces Board Changes

On February 6, 2015, the board of directors of Vaccinogen, Inc. elected Ronald Kaiser and Hakan Edstrom as directors of the company to fill vacancies on the board created by the resignation of John Nicolis and the an increase in the size of the board to six. Mr. Edstrom accepted his position as director of the company on February 6, 2015 and Mr. Kaiser accepted his position as director of the company on February 11, 2015. Mr. Kaiser was appointed to serve on the company’s Nominating and Corporate Governance Committee and Audit Committee. Mr. Kaiser will serve as Chairman of the Audit Committee in replacement of the currently serving Chairman. Mr. Edstrom was appointed to serve on the company’s Compensation Committee and Audit Committee. Mr. Edstrom will serve as Chairman of the Compensation Committee in replacement of the currently serving Chairman.

Vaccinogen Names Peter Morsing as Head of Business Development

Vaccinogen, Inc. announced that Peter Morsing, Ph.D., a 20-year pharmaceutical industry veteran, has joined the company as Head of Business Development. Dr. Morsing brings almost 20 years of pharmaceutical as well as business development experience to the Vaccinogen leadership team. Previously, he held roles of increasing responsibility with AstraZeneca, where he most recently served as Search and Evaluation Director and was responsible for identification and evaluation of novel therapeutic approaches to treat cardiovascular and metabolic diseases.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VGEN:US $3.70 USD -0.04

VGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VGEN.
View Industry Companies
 

Industry Analysis

VGEN

Industry Average

Valuation VGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VACCINOGEN INC, please visit www.vaccinogeninc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.